Novartis’ Secukinumab Sails Through Advisory Panel, Bodes Well For IL-17 Class
This article was originally published in The Pink Sheet Daily
Executive Summary
Unanimous advisory committee vote positions Novartis’ secukinumab to beat Lilly and Amgen/AstraZeneca competitors to market; panel supportive of Novartis’ preferred dose, letting other dosing issues be further explored post-market.
You may also be interested in...
Sun’s Tildrakizumab Deal: A Calculated Bet?
If approved, tildrakizumab, licensed in globally by Sun Pharma but developed by Merck, will be pitted against established competitors in a crowded market of advanced biologics for plaque psoriasis. But experts believe several advantages can help the top Indian generic firm leap into the wide world of dermatology and anti-inflammatory compounds.
Psoriasis Market Snapshot: An Area Drug Makers Are Itching To Get Into
The market for psoriasis drugs will become increasingly competitive, with several drugs with novel mechanisms of action approaching commercialization. Their challenge will be to demonstrate efficacy that stands up to existing biologics and an ultra-clean safety profile, given the notoriously cautious prescriber base.
Value-Based Pricing Bill with New Protections for Medicare and Medicaid Clears House Panel
Energy and Commerce Committee made some changes to a Trump-era regulation designed to make it easier for manufacturers to enter into value-based drug pricing contracts with commercial payers to limit unintended consequences for Medicaid and Medicare, but most Democrats say the tweaks don’t outweigh the harms of codifying the regulation.